BMS-561392. Bristol-Myers Squibb.
Bristol-Myers Squibb Pharma Co is developing the tumor necrosis factor-alpha (TNF alpha) converting enzyme inhibitor BMS-561392 (DPC-333) for the potential treatment of diseases characterized by overproduction of TNF alpha, such as rheumatoid arthritis (RA). A phase IIa trial in RA patients had commenced by April 2001, and by October 2002, BMS-561392 was also under investigation for the potential treatment of inflammatory bowel disease.